4,4,5,5-Tetramethyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-1,3,2-dioxaborolane → 1-[4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)thiazol-2-yl]piperidin-4-one

HRID 1401856노트

반응식

HRID 1401856 반응식
Br[C:2]1[N:3]=[C:4]([N:7]2[CH2:12][CH2:11][C:10](=[O:13])[CH2:9][CH2:8]2)[S:5][CH:6]=1.CC1(C)C(C)(C)OB([C:22]2[CH:31]=[CH:30][C:29]3[C:28]([CH3:33])([CH3:32])[CH2:27][CH2:26][C:25]([CH3:35])([CH3:34])[C:24]=3[CH:23]=2)O1>>[CH3:32][C:28]1([CH3:33])[CH2:27][CH2:26][C:25]([CH3:35])([CH3:34])[C:24]2[CH:23]=[C:22]([C:2]3[N:3]=[C:4]([N:7]4[CH2:12][CH2:11][C:10](=[O:13])[CH2:9][CH2:8]4)[S:5][CH:6]=3)[CH:31]=[CH:30][C:29]1=2

참가 물질

3

반응물 2

HCID 112439294,4,5,5-Tetramethyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-1,3,2-dioxaborolaneHCID 67323440HCID 67323440, 화합물

생성물 1

HCID 673225751-[4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)thiazol-2-yl]piperidin-4-one

실험 절차

The preparation is carried out as already described via a Suzuki reaction starting from 339 mg (1.18 mmol) of 1-(4-bromothiazol-2-yl)piperidin-4-one (preparation already described above) and 449 mg (1.30 mmol) of 4,4,5,5-tetramethyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-1,3,2-dioxaborolane.

후처리

  1. customas already described via a Suzuki reaction
  2. custompreparation

출처 및 근거

ORD 기록
ord-48fa92717509459db33f6ac68cd32e6d
출처 데이터셋
uspto-grants-2014_12
특허 번호
US08907098B2

반응 노트

불러오는 중…